ASCO® 2024 Summary: "Latest Practice-Changing Data in Gastroesophageal and Colorectal Cancers"
0:00 - Upper GI highlights: ESOPEC trial
1:33 - Upper GI highlights: RENAISSANCE and ARMANI trials
3:38 - Lower GI highlights: TRANSMET and COLLISION trials
5:54 - Lower GI highlights: NEOPRISM and Cercek trials
Do you want to find out about the latest practice-changing data in GI cancer? Watch this short video where international GI cancer experts provide the key highlights from data on upper and lower GI cancer presented at ASCO 2024 and the implications for clinical practice.
For upper GI cancer, Dr Lizzy Smyth (UK) and Dr Sam Klempner (US) provide their key clinical takeaways from the ESOPEC trial (FLOT vs CROSS in oesophageal cancer), RENAISSANCE (radical surgical resection in gastroesophageal cancer) and ARMANI (ramucirumab plus paclitaxel in HER-2 negative gastric/gastroesophageal cancer).
For lower GI cancer, Prof Jenny Seligmann (UK) and Dr Dominik Modest provide the highlights from TRANSMET (chemotherapy and liver transplantation vs chemotherapy alone in patients with definitively unresectable colorectal liver metastases), COLLISION (surgery vs thermal ablation for small-size colorectal liver metastases), NEOPRISM (pembrolizumab in dMMR/MSI-high colorectal cancer) and a trial on PD-1 blockade in MMR-deficient locally advanced rectal cancer.
1:33 - Upper GI highlights: RENAISSANCE and ARMANI trials
3:38 - Lower GI highlights: TRANSMET and COLLISION trials
5:54 - Lower GI highlights: NEOPRISM and Cercek trials
Do you want to find out about the latest practice-changing data in GI cancer? Watch this short video where international GI cancer experts provide the key highlights from data on upper and lower GI cancer presented at ASCO 2024 and the implications for clinical practice.
For upper GI cancer, Dr Lizzy Smyth (UK) and Dr Sam Klempner (US) provide their key clinical takeaways from the ESOPEC trial (FLOT vs CROSS in oesophageal cancer), RENAISSANCE (radical surgical resection in gastroesophageal cancer) and ARMANI (ramucirumab plus paclitaxel in HER-2 negative gastric/gastroesophageal cancer).
For lower GI cancer, Prof Jenny Seligmann (UK) and Dr Dominik Modest provide the highlights from TRANSMET (chemotherapy and liver transplantation vs chemotherapy alone in patients with definitively unresectable colorectal liver metastases), COLLISION (surgery vs thermal ablation for small-size colorectal liver metastases), NEOPRISM (pembrolizumab in dMMR/MSI-high colorectal cancer) and a trial on PD-1 blockade in MMR-deficient locally advanced rectal cancer.
Comments 0
Login to view comments.
Click here to Login
